U.S. FDA extends review of Bristol Myers' cancer therapy acquired in Celgene deal

Bristol Myers Squibb said on Wednesday the U.S. drug regulator had extended the review of its experimental blood cancer therapy by three months after the drugmaker submitted additional information to the agency.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news